Earlier this afternoon, BioAtla, Inc. released financial results and a business update for the quarter ended 09/30/2025.

Elisabeth Fay is a clinical associate professor in CAS, and an elected member of CFU-UAW’s Bargaining Committee. My union, ...

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary ...

Atea Pharmaceuticals, Inc. ( AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements November 13, 2025 10:00 AM EST Jordan Feld Anthony Martinez Nancy Reau Eric ...

ROHM has released the industry-first AI MCUs capable of standalone learning and inference, specifically developed to enable predictive maintenance.

BioAtla’s Q3 2025 update details FDA-aligned Oz-V Phase III trial, peak sales forecast, strategic deal progress, and cost reductions.

If NHS Talking Therapies work so well, why are recovery rates lower for young adults? Saunders and colleagues analysed data ...

Following publication of KEYNOTE-689 Phase 3 results confirming the role of perioperative checkpoint inhibition in head and neck cancer, GeoVax announced plans for a Phase 2 trial (AdPNP-203) ...

Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today ...